Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

neuraxpharm bohemia s.r.o., Česká republika - pregabalín - 21 - antiepileptica, anticonvulsiva

Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

neuraxpharm bohemia s.r.o., Česká republika - pregabalín - 21 - antiepileptica, anticonvulsiva

Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

neuraxpharm bohemia s.r.o., Česká republika - pregabalín - 21 - antiepileptica, anticonvulsiva

Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

neuraxpharm bohemia s.r.o., Česká republika - pregabalín - 21 - antiepileptica, anticonvulsiva

Unione Europea - slovacco - EMA (European Medicines Agency)

almirall, s.a. - tirbanibulin - keratóza, aktinická - antibiotiká a chemoterapeutiká na dermatologické použitie - klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (olsen grade 1) of the face or scalp in adults.

Unione Europea - slovacco - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - lieky používané pri cukrovke - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Unione Europea - slovacco - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - ertapenem sodný - bakteriálne infekcie - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 a 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. je treba vziať do úvahy oficiálne usmernenie o vhodnom používaní antibakteriálne agentov.

Unione Europea - slovacco - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatid - osteoporosis; osteoporosis, postmenopausal - homeostáza vápnika - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Unione Europea - slovacco - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatitída, atopická - ostatné dermatologické prípravky - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

Unione Europea - slovacco - EMA (European Medicines Agency)

eli lilly nederland b.v. - inzulín glargín - cukrovka - lieky používané pri cukrovke - liečba diabetes mellitus u dospelých, dospievajúcich a detí vo veku od 2 rokov.